Lion's Mane (Hericium erinaceus) is a shaggy, white culinary mushroom that has become one of the most talked-about "brain mushrooms" on the market, built almost entirely on one mechanism: compounds in the mushroom appear to stimulate nerve growth factor (NGF), a protein that supports the growth and survival of neurons. That mechanism is real and well-documented — in cell cultures and in animals. In humans, the picture is thinner and more mixed than the marketing suggests. A handful of small randomized controlled trials, ranging from 18 to 41 participants, have tested Lion's Mane against placebo for cognition, mood and stress. Some found real, statistically significant effects on specific measures; others found nothing, and one even found a negative result on a memory test. Nobody has yet run a large, long trial in a general adult population and shown a clear, repeatable cognitive benefit. This is an honest look at what the NGF story actually rests on, what the human trials say, and why Lion's Mane isn't in Proco's range today — not because it fails our category-fit standard, but because the evidence doesn't yet clear the bar the rest of our range is held to.
Evidence reviewed: September 2026.
What Lion's Mane is, and the mechanism behind the hype
Lion's Mane has a long history as a culinary and traditional-medicine mushroom in China and Japan (known there as Yamabushitake), but its modern nootropic reputation traces back to a specific discovery: two families of compounds unique to the mushroom — hericenones, found in the fruiting body, and erinacines, found in the mycelium — were shown in laboratory and animal research to stimulate NGF biosynthesis.6 NGF is a protein your body already produces; it supports the growth, maintenance and survival of certain neurons, and reduced NGF signaling has been studied as one factor in age-related cognitive decline. The logic of the supplement case is straightforward: if a compound can boost NGF production, and NGF supports neuron health, then a mushroom extract might support brain function over time.
That logic is reasonable, but it's also exactly where most of the coverage stops — at the mechanism, not the outcome. The NGF-stimulating effect has been demonstrated in cell culture (human astrocytoma cells) and in rodent studies, where erinacine-treated animals showed increased NGF mRNA expression in brain tissue.6 Nobody has directly measured whether oral Lion's Mane raises NGF levels in the human brain — that's not something you can currently test non-invasively and ethically in living people. What human trials can measure is downstream: does taking Lion's Mane actually change cognitive test scores, mood, or self-reported stress? That's a different, and much harder, question — and it's the one that matters for whether the ingredient does anything for you.
What the human trials actually show
As of this review, four small randomized, placebo-controlled human trials and one broader systematic review make up the core evidence base. Here's each one, plainly.
| Trial | Population / n | Dose & duration | Result |
|---|---|---|---|
| Mori et al., 20091 | Adults 50-80 with mild cognitive impairment, n=30 | 3g/day fruiting-body powder, 16 weeks | Cognitive scale scores rose significantly by weeks 8-16 vs. placebo — but fell back significantly within 4 weeks of stopping |
| Saitsu et al., 20192 | Healthy adults, n=31 | Not fully disclosed, 12 weeks | Significant improvement on 1 of 3 cognitive tests (MMSE); the other two showed no significant change |
| Docherty et al., 20233 | Healthy adults 18-45, n=41 | 1.8g/day, single dose + 28 days | Faster Stroop task performance at 60 min post-dose (p=0.005); a non-significant trend toward lower stress at 28 days (p=0.051); null results and one significant negative finding on a word-recall measure |
| Surendran et al., 20254 | Healthy adults 18-35, n=18 | Single 3g acute dose (crossover) | No significant effect on overall cognition or mood composites; an isolated improvement on one psychomotor (pegboard) test |
Across four trials and 120 total participants, the pattern isn't "Lion's Mane works" or "Lion's Mane doesn't work" — it's one or two positive measures per study, embedded in a larger set of null results, in different populations, at different doses, for different durations.
A 2025 systematic review pooling this evidence — five RCTs and three pilot trials in total, covering both dementia and non-dementia populations — found a modest combined effect on one standard cognitive measure (MMSE scores rose by a weighted average of 1.17 points in treated groups) and reported that some trials also measured reduced anxiety, depressive symptoms and sleep disturbance, alongside preclinical evidence of increased BDNF (a related neurotrophic factor) and hippocampal neurogenesis.5 The review's own authors frame Lion's Mane as promising rather than proven, and are explicit that side effects are inconsistently reported across the underlying studies — a limitation in the evidence base itself, not just a safety footnote.
The Mori 2009 result is worth sitting with a moment longer, because it's the most-cited trial and also the most instructive about what this evidence does and doesn't show. Cognitive scores improved steadily over 16 weeks of continuous use — then dropped significantly within a month of stopping. That pattern is more consistent with a temporary, use-dependent effect than a lasting structural change to the brain, and it means any real benefit here would likely require ongoing, indefinite use rather than a short course.
Why the sample sizes matter
Trials this small — 18, 30, 31, 41 participants — aren't automatically wrong, but they're statistically fragile. A single outlier participant, a slightly different test battery, or a marginally different dose can flip a result from significant to null, or vice versa. That's plausibly part of why these four trials, testing broadly similar things, land on different specific measures being the ones that improved. None of this means Lion's Mane doesn't do anything — it means the evidence isn't yet at the size and consistency where you can say with confidence what it reliably does, for whom, at what dose.
Safety
Across the trials and case reports reviewed, Lion's Mane has generally been well-tolerated, with the most commonly reported issues being mild gastrointestinal discomfort, nausea or skin rash; one case report has documented possible respiratory distress in a person with a mushroom sensitivity.5 Long-term safety data beyond the duration of these short trials (up to 16 weeks) doesn't yet exist. As with any mushroom-derived supplement, anyone with a known mushroom or fungal allergy should avoid it.
Where this leaves Lion's Mane at Proco
Proco's product-selection standard is category fit plus basic safety, not evidence-depth gating — Lion's Mane clearly fits the category, aimed squarely at cognitive and nervous-system support. On category grounds alone, it's a legitimate candidate for future consideration. It isn't in the range today because the human outcome data — as opposed to the NGF mechanism — is still thin: four small trials, inconsistent results even within single studies, and no replication of any single finding by an independent research group yet. That's a different, more basic bar than requiring "multiple independent RCTs," and it's one Lion's Mane hasn't cleared yet. If a larger, well-powered trial replicates a specific, meaningful effect — the kind of result Cognitive Support's current ingredients like Bacopa monnieri and Alpha GPC already have behind them — that changes the calculus. For now, the honest answer is: promising mechanism, real but preliminary human signal, not yet enough to put our name on it.
Bottom line
Lion's Mane has the most scientifically interesting mechanism of any ingredient we've reviewed that isn't currently in our range — a genuinely novel, cell-and-animal-confirmed pathway for supporting nerve growth. But mechanism isn't outcome, and the human trial record is still four small studies deep, with results that shift depending on which test you look at. If you're already taking Lion's Mane and it seems to be working for you, that's a reasonable, low-risk thing to continue — the safety profile is good. If you're deciding whether to start, go in with accurate expectations: this is a promising, early-stage ingredient, not a settled one, and the case for it today rests more on mechanism than on consistent human outcome data.
This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.
References
- Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. "Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial." Phytotherapy Research, 2009;23(3):367-372. pubmed.ncbi.nlm.nih.gov
- Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. "Improvement of cognitive functions by oral intake of Hericium erinaceus." Biomedical Research, 2019;40(4):125-131. pubmed.ncbi.nlm.nih.gov
- Docherty S, Doughty FL, Smith EF. "The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study." Nutrients, 2023;15(22):4842. pmc.ncbi.nlm.nih.gov
- Surendran G, Saye J, Jalil SBM, et al. "Acute effects of a standardised extract of Hericium erinaceus (Lion's Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study." Frontiers in Nutrition, 2025;12:1405796. frontiersin.org
- Menon A, Jalal A, Arshad Z, Nawaz FA, Kashyap R. "Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review." Frontiers in Nutrition, 2025;12:1641246. pubmed.ncbi.nlm.nih.gov
- Kawagishi H, Zhuang C. "Hericenones and erinacines: stimulators of nerve growth factor (NGF) biosynthesis in Hericium erinaceus." International Journal of Medicinal Mushrooms. tandfonline.com
Related reading: Why We Don't Sell "Brain Blends" (And What Actually Clears Our Bar) · Bacopa Monnieri: The Evidence Is Real, But It Takes Weeks · NAC: Real Evidence, Real Nuance
See what's currently in Cognitive Support today — 10 ingredients chosen on the same standard this article holds Lion's Mane to.